Protease inhibitor-based therapy is associated with decreased HIV- related health care costs in men treated at a veterans administration hospital

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 1, 1999, Pages 28-33

  Keiser, Philip ^a   Kvanli, Mary Beth ^b   Turner, Dianna ^b   Reisch, Joan ^a   Smith, James W ^a,b   Nassar, Naiel ^a,b   Gregg, Clark ^a,b   Skiest, Daniel ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

HIV related health costs; Protease inhibitor

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION RATE; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINASE INHIBITION; SOLDIER; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032900149     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199901010-00004     Document Type: Article

References (18)

1. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995;;23:1528-33.
2. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333;23:1534-9.
3. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996 173;2:321-9.
4. + T-cell counts in HIV-infected patients. Ann Intern Med 1996;124;12:1039-50.
5. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334;16:1011-7.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS. N Engl J Med 1997;337:725-33.
7. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996;276: 146-54.
8. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-05).
9. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-53.
10. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. An economic perspective. Pharmacoeconomics 1996; 10:109-13.
11. Update: trends in AIDS incidence - United States, 1996. MMWR 1997;46:37.
12. Palella FJ Jr, Delaney KM, Moorman AC, et al. HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853.
13. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. An economic perspective. Pharmacoeconomics 1996; 10:109-13.
14. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census N Engl J Med 1997;336;21:1531-2.
15. Beck EJ, Kupek EJ, Wadsworth J, Miller DL, Piching AJ, Harris JRW. The use and costs of hospital services by London AIDS patients with different AIDS defining conditions. J Public Health Med 1996 18;4:457-64.
16. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14: 223-31.
17. Hellinger FJ. The life time costs of treating a person with HIV infection. JAMA 1993;270:474-8.
18. AIDS in New York State through 1994. Albany, NY: New York Health Department of Health, 1996.